Loading...
•
Dec 31, 2023
Liquidia Q4 2023 Earnings Report
Reported full year financial results and provided a corporate update.
Key Takeaways
Liquidia Corporation reported its full year 2023 financial results, with a net loss of $78.5 million. The company is preparing for the commercial launch of YUTREPIA following favorable court decisions and awaiting final FDA approval.
Invalidity of sole patent supporting injunction was affirmed in appeal proceedings at the Federal Circuit.
Awaiting final FDA approval of YUTREPIA to treat PAH and PH-ILD after March 31, 2024.
Advancing industry leading portfolio for inhaled treprostinil between YUTREPIA and sustained-release program, L606.
Cash and cash equivalents totaled $83.7 million as of December 31, 2023.
Liquidia
Liquidia
Forward Guidance
Liquidia is preparing to become a full-scale commercial entity in 2024 and initiate meaningful change to the lives of patients diagnosed with PAH and PH-ILD.
Positive Outlook
- Positioned to be ready for launch of YUTREPIA in both indications following the expiration of Tyvaso’s market exclusivity on March 31, 2024.
- Confident that the medical community will see first-hand that YUTREPIA has the potential to not only be the best in class inhaled product.
- YUTREPIA has a convenient, low-effort delivery and wide dosing range enabled by our proprietary PRINT Technology.
- Liquidia plans to complete enrollment of all 60 patients in ASCENT study in 2024 and will share interim data at upcoming conferences.
- Preparing to initiate the global PH-ILD study by the end of 2024.